Eli Lilly was among the investors in neurodegenerative disease drug developer Vanqua Bio’s $85m series B round.

RBVC has re-upped its commitment to the construction data platform developer having also backed its series A and seed rounds in the past two years.

Lilly Asia Ventures has returned to reinvest in the renal disease therapy developer through a series B-plus round totalling $54.5m.

Samsung-backed automation software developer Rezilion secured $30m while IGC Hospitality took part in restaurant management technology provider MarginEdge's $18m series B round.

Allegis Group and SiriusPoint helped the online business insurance provider reach $160m of overall funding, reportedly boosting its valuation to $550m.

Bristol Myers Squibb helped the cell encapsulation technology developer raise cash that will help fund its international growth.

The micro-investment platform developer closed its latest round with backing from Susquehanna International Group, Gojek and UOB.

Ningbo Water Meter has contributed to a $77.6m round for the IoT chip manufacturer, which also counts Septwolves as an existing investor.

Amgen, Bristol Myers Briggs and Vertex Pharmaceuticals were among the investors that brought the gene therapy developer’s overall funding to over $164m.

The gene therapy developer secured backing from Lundbeck and Alexandria Real Estate Equities in a series B round that will support the advancement of its clinical pipeline.